Biomarin

Up on Deck! Ten Q3 Biotech Earnings Reports to Watch Next Week
Up on Deck! Ten Q3 Biotech Earnings Reports to Watch Next Week
BioSpace
earnings
biotech
Biogen
Alexion Pharmaceuticals
Bristol-Myers Squibb
Celgene
Gilead Sciences
Merck
Biomarin
Galapagos
Seattle Genetics
Dr Reddy's
Flag link:
3 Biotech Stocks With Virtual Monopolies
3 Biotech Stocks With Virtual Monopolies
Motley Fool
Alexion Pharmaceuticals
Biomarin
Vertex Pharmaceuticals
Flag link:
Express Scripts staking out million-dollar gene therapies
Express Scripts staking out million-dollar gene therapies
Reuters
Express Scripts
PBMs
gene therapies
drug pricing
Biomarin
Bluebird Bio
Spark Therapeutics
Flag link:
BioMarin Pharmaceutical Sets Its Sights on $2 Billion
BioMarin Pharmaceutical Sets Its Sights on $2 Billion
Motley Fool
Biomarin
earnings
Flag link:
BioMarin Begins Pediatric Study on Achondroplasia Candidate
BioMarin Begins Pediatric Study on Achondroplasia Candidate
Yahoo/Zacks.com
Biomarin
clinical trials
vosoritide
achrondoplasia
Flag link:
Two drugs in the pipeline representing unique marketing challenges
Two drugs in the pipeline representing unique marketing challenges
Medical Marketing and Media
valrox
Biomarin
hepatitis A
risankizumab
AbbVie
Boehringer Ingelheim
psoriasis
Flag link:
BioMarin Rises on Approval of Palynziq (pegvaliase-pqpz)
BioMarin Rises on Approval of Palynziq (pegvaliase-pqpz)
CP Wire
Biomarin
Palynziq
PKU
FDA
Flag link:
BioMarin Rises on Approval of Palynziq (pegvaliase-pqpz)
Biomarin
Palynziq
PKU
Flag link:
A Big Decision Is Fast-Approaching for This Rare-Disease Drugmaker
A Big Decision Is Fast-Approaching for This Rare-Disease Drugmaker
Motley Fool
Biomarin
pegvaliase
PKU
FDA
Flag link:
Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study
Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study
Endpoints
Biomarin
hemophilia A
valrox
Flag link:
BioMarin Cruises While It Waits on Seventh Approval
BioMarin Cruises While It Waits on Seventh Approval
Motley Fool
Biomarin
pegvaliase
FDA
PKU
earnings
Flag link:
8 Takeout targets to watch in 2018
8 Takeout targets to watch in 2018
BioPharma Dive
M&A
Allergan
Alnylam
Biomarin
Bristol-Myers Squibb
Incyte
Madrigal Pharmaceuticals
Spark Therapeutics
Sucampo
Flag link:
[video]ASH 2017 Recap: These Were the Big Winners and Losers
[video]ASH 2017 Recap: These Were the Big Winners and Losers
Motley Fool
ASH2017
Bluebird Bio
Juno Therapeutics
Spark Therapeutics
Biomarin
JNJ
Celgene
Flag link:
ASH 2017: What you missed
ASH 2017: What you missed
BioPharma Dive
ASH17
Biomarin
Spark Therapeutics
Gilead Sciences
Novartis
Juno Therapeutics
AbbVie
Roche
JNJ
Flag link:
5 Biotech Buyout Candidates for 2018
5 Biotech Buyout Candidates for 2018
Yahoo/Motley Fool
biotech
M&A
Biogen
Biomarin
Bluebird Bio
Geron
SAGE Therapeutics
Flag link:
ASH17: Spark gene therapy falls behind BioMarin in hemophilia
ASH17: Spark gene therapy falls behind BioMarin in hemophilia
BioPharma Dive
ASH17
Spark Therapeutics
gene therapy
Biomarin
hemophilia A
SPK-8011
Flag link:
ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia
ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia
BioPharma Dive
ASH17
Biomarin
gene therapy
hemophilia A
valoctocogene
Flag link:
How much is an FDA shortcut worth to drug developers hustling to an OK? Holding steady at $125M, cash
How much is an FDA shortcut worth to drug developers hustling to an OK? Holding steady at $125M, cash
Endpoints
FDA
priority review vouchers
Biomarin
Flag link:
9 Notable Biotechs Presenting At This Year's ASH Meeting
9 Notable Biotechs Presenting At This Year's ASH Meeting
Yahoo
ASH
Bluebird Bio
LentiGlobin
Ziopharm Oncology
Bellicum
BPX-501
Spark Therapeutics
SPK-8011
Biomarin
BMN 270
Juno Therapeutics
CAR-T
Novartis
Geron
imetelstat
Immunogen
IMGN632
IMGN779
Flag link:
With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy
With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy
Endpoints
Biomarin
gene therapy
BMN 270
hemophilia A
Flag link:

Pages